AstraZeneca (NYSE:AZN) issued an update on its FY 2018 earnings guidance on Thursday morning. The company provided earnings per share guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.68. AstraZeneca also updated its FY18 guidance to $3.30-3.50 EPS.
Shares of NYSE AZN opened at $40.97 on Friday. The stock has a market cap of $99.31 billion, a PE ratio of 9.57, a price-to-earnings-growth ratio of 2.09 and a beta of 0.57. AstraZeneca has a 1 year low of $31.99 and a 1 year high of $41.28. The company has a quick ratio of 0.54, a current ratio of 0.72 and a debt-to-equity ratio of 1.08.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, November 8th. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.38. The firm had revenue of $5.34 billion during the quarter, compared to analysts’ expectations of $5.26 billion. AstraZeneca had a net margin of 11.98% and a return on equity of 29.89%. The business’s revenue was down 14.3% on a year-over-year basis. During the same period last year, the company earned $1.12 earnings per share. As a group, research analysts anticipate that AstraZeneca will post 1.67 EPS for the current fiscal year.
In other news, major shareholder Plc Astrazeneca purchased 600,000 shares of the company’s stock in a transaction that occurred on Monday, October 22nd. The shares were bought at an average cost of $5.00 per share, with a total value of $3,000,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.